Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial.

ABSTRACT:

Background

Medication development research for cocaine use disorder (CUD) has been a longstanding goal in addiction research, but has not resulted in an FDA-approved treatment. Rising cocaine use rates underscore the need for efficient adaptive designs. This study compared differences between two doses of the selective serotonin reuptake inhibitor (SSRI) citalopram (versus placebo) on duration of cocaine abstinence and applied adaptive decision rules to select the 'best efficacy' dose.

Methods

A double-blind, placebo-controlled, randomized Bayesian drop-the-loser (DTL) trial with three arms compared placebo to citalopram 20 mg and 40 mg. Adults (N = 107) with CUD attended thrice-weekly clinic visits for 9 weeks. The primary outcome was longest duration of abstinence (LDA), b

SUBMITTER: Suchting R 

PROVIDER: S-EPMC8595787 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature